RecruitingNot ApplicableNCT06848166

CHROnic Migraine Embolization

Study of the Effectiveness and Safety of Embolization of the Middle Meningeal Artery Using Non-adhesive Materials SQUID 12 and SQUID 18 in the Treatment of Patients With Chronic Resistant Migraine


Sponsor

Vedanta University Clinic

Enrollment

30 participants

Start Date

Oct 17, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

To evaluate the effectiveness and safety of middle meningeal artery (MMA) embolization using non-adhesive materials SQUID 12 and SQUID 18 as a treatment method for patients with chronic resistant migraine.


Eligibility

Min Age: 21 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called liquid embolic agent SQUID 12, liquid embolic agent SQUID 18 for people with chronic migraine, headache. The study is currently recruiting participants at 1 location. People eligible for this study include aged 35 Years to 59 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEliquid embolic agent SQUID 12, liquid embolic agent SQUID 18

Total endovascular embolization of the frontal and parietal branches (less often the occipital branch) of the middle meningeal artery (MMA) with its complete devascularization. In the case of unilateral pain localization, ipsilateral MMA embolization will be performed; in the case of bilateral pain localization, total embolization of both MMA branches will be performed.


Locations(1)

Vedanta University Clinic

Bishkek, Bishkek, Kyrgyzstan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06848166


Related Trials